Global Next-Generation Cancer Diagnostics Market Research Report (up to 2027)
Next-Generation Cancer Diagnostics Market Globally (up to 2027): By Technology, By Cancer Type, By Function, By Application, By Region
360iResearch predicts that the global next-generation cancer diagnostics market, which was valued at $7,006.17 million in 2021, will reach $8,638.56 million in 2022 and expand to $24,830.48 million by 2027, growing at a CAGR of 23.47%. This research report analyzes the global market for next-generation cancer diagnostics from multiple perspectives, including an introduction, research methodology, executive summary, market overview, market insights, analysis by technology (DNA microarrays, lab-on-chip & reverse transcription enzyme PCR, next-generation sequencing, protein microarrays, qPCR & multiplex), analysis by cancer type (breast cancer, cervical cancer, colorectal cancer, lung cancer), analysis by function (cancer screening, companion diagnostics, prediction, risk analysis, treatment monitoring), analysis by application (biomarker development, CTC analysis, epigenetic analysis, genetic analysis, proteomic analysis), regional analysis (North America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, others), competitive landscape, and company information.
- Company：マーケットリサーチセンター
- Price：Other
